OTLK is up 8% today after resubmitting application for macular degeneration drug

Outlook Therapeutics Inc (OTLK) is trading 8% higher at $1.205 today. While it's a mildly gloomy day for the Health Care sector in general, the stock is outshining it's peers.

-Outlook Therapeutics Inc has resubmitted an application to the FDA for a drug called ONS-5010, which is used to treat wet age-related macular degeneration.
-The company's CEO says they have worked hard over the past three months to provide additional information that was not included in the original submission.

Outlook Therapeutics Inc has been trading between a 52-week high of $2.87 and a 52-week low of $0.6839. The stock has a market cap of $273 Million.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.